Production of Adenovector Based Vaccines

Award Information
Agency: Department of Health and Human Services
Branch: N/A
Contract: 1R43AI063819-01
Agency Tracking Number: AI063819
Amount: $598,088.00
Phase: Phase I
Program: SBIR
Awards Year: 2005
Solicitation Year: 2005
Solicitation Topic Code: N/A
Solicitation Number: PHS2005-2
Small Business Information
GENVEC, INC.
Genvec, Inc., 65 W Watkins Mill Rd, Gaithersburg, MD, 20878
DUNS: N/A
HUBZone Owned: N
Woman Owned: N
Socially and Economically Disadvantaged: N
Principal Investigator
 DUNCAN MCVEY
 (240) 632-5546
 DMCVEY@GENVEC.COM
Business Contact
Phone: (240) 632-5537
Research Institution
N/A
Abstract
DESCRIPTION (provided by applicant): Adenovirus vectors (AdVectors) designed to express an antigenic gene have shown great promise as vaccines. Although GenVec and other groups have constructed numerous AdVectors expressing a variety of antigens a substantial subset of antigen genes have been found to be inhibitory to AdVector construction and production. In this phase I SBIR proposal we will investigate strategies to circumvent the deleterious effect of inhibitory genes by blocking antigen expression within the AdVector production cell line. These results will guide the building, certification and banking of a commercial cell line during SBIR Phase II. A cell line broadly applicable for production of AdVectors containing inhibitory transgenes is presently not available. During SBIR phase I two different mechanisms of repressing expression, transcriptional and post-transcriptional, will be tested. Aim 1 will optimize a transcriptional repressor, incorporate it into a cell line and demonstrate its functionality on AdVectors with inhibitory genes. Aim 2 will test the hypothesis that a single siRNA can be broadly applied to inhibit transgene expression. It is anticipated that both strategies will be used in the ultimate cell line constructed in phase II. The final GMP manufacturing cell line will speed and facilitate the testing of advector vaccine concepts for many antigens, speed their progress to clinical testing and reduce the cost of goods for future approved vaccine products.

* information listed above is at the time of submission.

Agency Micro-sites

SBA logo
Department of Agriculture logo
Department of Commerce logo
Department of Defense logo
Department of Education logo
Department of Energy logo
Department of Health and Human Services logo
Department of Homeland Security logo
Department of Transportation logo
Environmental Protection Agency logo
National Aeronautics and Space Administration logo
National Science Foundation logo
US Flag An Official Website of the United States Government